L 315/8 Official Journal of the European Union 2.12.2009 COMMISSION DECISION of 27 November 2009 amending Annexes XI, XII, XV and XVI to Council Directive 2003/85/EC as regards the list of and minimum security standards applicable to laboratories authorised to handle live foot-and-mouth disease virus (notified under document C(2009) 9094) (Text with EEA relevance) (2009/869/EC) THE COMMISSION OF THE EUROPEAN COMMUNITIES, Having regard to the Treaty establishing the European Community, Having regard to Council Directive 2003/85/EC of 29 September 2003 on Community measures for the control of foot-and-mouth disease repealing Directive 85/511/EEC and Decisions 89/531/EEC and 91/665/EEC and amending Directive 92/46[EEC (1), and in particular Articles 67(2) and 87(3) thereof, Whereas: (1)  Directive 2003/85/EC sets out minimum control measures to be applied in the event of an outbreak of foot-and-mouth disease and certain preventive measures aimed at increasing the awareness and preparedness of the competent authorities and the farming community concerning that disease. (2)  Article 65 of Directive 2003/85/EC provides that Member States are to ensure that the handling of live foot-and-mouth disease virus for research, diagnosis or manufacture is carried out only in approved laboratories listed in Annex XI and operated at least according to the bio-security standards set out in Annex XII to that Directive. (3)  Part A of Annex XI to Directive 2003/85/EC lists national laboratories authorised to handle live foot-and- mouth disease virus for research and diagnostic purposes. Part B of that Annex lists laboratories handling virus antigen during the manufacture of vaccines. (4)  France has officially informed the Commission that one of their national reference laboratories and a vaccine manufacturing laboratory are no longer considered to meet the bio-security standards provided for in Article 65(d) of Directive 2003/85/EC. () O] L 306, 22.11.2003, p. 1. () The Netherlands have officially informed the Commission of a further change of name of their national diagnostic laboratory authorised to handle live foot-and-mouth disease virus, and of the takeover by the private company ‘Lelystad Biologicals BV, Lelystad’ of that part of the former Central Institute for Animal Disease Control (CIDC-Lelystad) authorised to handle live foot- and-mouth disease virus for the production of vaccines. It is therefore necessary to amend the lists of laboratories authorised to handle live foot-and-mouth disease virus set out in Annex XI to Directive 2003/85/EC. Point 1 of Annex XII to Directive 2003/85/EC sets out bio-security standards for laboratories handling live foot- and-mouth disease virus. It provides that such labora- tories are to meet or exceed the minimum requirements laid down in the ‘Minimum standards for laboratories working with foot-and-mouth virus in vitro and in vivo' established by the European Commission for the control of foot-and-mouth disease, 26th session, Rome, April 1985, as modified in 1993. Point 1 of Annex XV to Directive 2003/85/EC provides that all national laboratories handling live foot-and- mouth disease virus are to operate under high security conditions laid down in ‘Minimum standards for labora- tories working with foot-and-mouth disease virus in vitro and in vivo, European Commission for the control of foot-and-mouth disease — 26th Session, Rome, 1985, as amended by Appendix 6(ii) of the Report of the 30th Session, Rome, 1993. In addition, point 7 of Annex XVI to Directive 2003/85/EC provides that the Community Reference Laboratory is to operate according to recognised conditions of strict disease security as indicated in ‘Minimum standards for laboratories working with foot- and-mouth disease virus in vitro and in vivo', European Commission for the control of foot-and-mouth disease — 26th Session, Rome, April 1985, as amended by Appendix 6 (i) of the report to the 30th Session of the European Commission for the control of foot-and- mouth disease 1993, referred to in Annex XII to that Directive.